Why is Alivus Life falling/rising?

As of 14-Aug, Alivus Life Sciences Ltd is experiencing a decline in its stock price, currently at Rs 941.40, which reflects a decrease of Rs 20.2 or 2.1%. The stock has underperformed its sector by 2.22% today and has fallen after two consecutive days of gains. It touched an intraday low of Rs 936.6, indicating a downward trend. Over the past week, the stock has shown a modest increase of 1.23%, but it has significantly underperformed over the last month with a decline of 12.99%. Despite a high management efficiency indicated by a return on equity (ROE) of 19.11% and a low debt-to-equity ratio, the stock is trading at a premium compared to its peers, which may be contributing to investor hesitation. Additionally, the company has shown poor long-term growth with net sales growing at an annual rate of only 4.49% over the last five years.
In the broader market context, the Sensex has remained relatively flat, with a slight decline of 0.03% over the past week. While Alivus Life's short-term performance has been better than the benchmark, its longer-term returns are concerning, with a year-to-date decline of 4.81% compared to the Sensex's gain of 3.15%. The falling investor participation, as evidenced by an 81.58% drop in delivery volume against the five-day average, suggests a lack of confidence among investors, further exacerbating the stock's downward movement. Overall, the combination of poor long-term growth prospects, high valuation relative to peers, and declining investor interest is likely driving the stock's current decline.